[PD-1/L1抑制剂在头颈部鳞状细胞癌治疗中的研究进展]
[The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
作者信息
Song Pan, Yan Xiaoqing, Jiang Yanhui, Ye Yuchu, Wang Jingyi, Han Ping
出版信息
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Apr;36(4):315-320. doi: 10.13201/j.issn.2096-7993.2022.04.017.
Abstract
Over the past few years, the FDA has approved PD-1/L1 inhibitor for the treatment of advanced head and neck squamous cell carcinoma, involving PD-1/L1 inhibitor monotherapy, PD-1/L1 inhibitor combined with chemoradiotherapy, combined with targeted therapy, combined with neoadjuvant immunotherapy and duplex-block of immune checkpoints and so on. Herein, we briefly review the latest research results in this field, and summarize the application and efficacy of immunotherapy in the treatment of head and neck squamous cell carcinoma， which will benefits such patients to develop more precise and individualized treatment plans.
摘要
在过去几年中，美国食品药品监督管理局（FDA）已批准PD-1/L1抑制剂用于治疗晚期头颈部鳞状细胞癌，包括PD-1/L1抑制剂单药治疗、PD-1/L1抑制剂联合放化疗、联合靶向治疗、联合新辅助免疫治疗以及免疫检查点双重阻断等。在此，我们简要回顾该领域的最新研究成果，并总结免疫疗法在头颈部鳞状细胞癌治疗中的应用及疗效，这将有助于此类患者制定更精准、个性化的治疗方案。
相似文献
1
[The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].[PD-1/L1抑制剂在头颈部鳞状细胞癌治疗中的研究进展]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Apr;36(4):315-320. doi: 10.13201/j.issn.2096-7993.2022.04.017.
2
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.头颈部肿瘤中 PD-1/PD-L1 通路的演变格局。
Front Immunol. 2020 Sep 18;11:1721. doi: 10.3389/fimmu.2020.01721. eCollection 2020.
3
The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.免疫治疗时代 PD-1/PD-L1 阻断在头颈部鳞状细胞癌（HNSCC）中的当前进展和未来方向。
Int Immunopharmacol. 2023 Jul;120:110329. doi: 10.1016/j.intimp.2023.110329. Epub 2023 May 17.
4
Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.头颈部鳞状细胞癌患者的新辅助PD-1/PD-L1轴阻断治疗
Am J Otolaryngol. 2023 Nov-Dec;44(6):103985. doi: 10.1016/j.amjoto.2023.103985. Epub 2023 Jul 5.
5
Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.评估头颈部鳞状细胞癌患者细胞学中程序性死亡配体 1 的表达，以确定其是否适合接受免疫检查点抑制剂治疗。
Cancer Cytopathol. 2022 Feb;130(2):110-119. doi: 10.1002/cncy.22501. Epub 2021 Aug 10.
6
PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.PD-1/PD-L1抑制剂联合化疗与标准治疗方案用于复发性或转移性头颈部鳞状细胞癌一线治疗的比较
Eur Arch Otorhinolaryngol. 2023 Jan;280(1):1-9. doi: 10.1007/s00405-022-07571-9. Epub 2022 Jul 30.
7
Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中免疫检查点抑制剂的当前和未来生物标志物。
Curr Oncol. 2022 Jun 8;29(6):4185-4198. doi: 10.3390/curroncol29060334.
8
Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.头颈部癌症中免疫检查点抑制剂的治疗方法及PD-L1作为生物标志物的作用
Cancer Control. 2021 Jan-Dec;28:10732748211004878. doi: 10.1177/10732748211004878.
9
Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.程序性死亡受体 1/程序性死亡配体 1 轴阻断在复发性或转移性头颈部鳞状细胞癌中按人乳头瘤病毒状态分层：系统评价和荟萃分析。
Front Immunol. 2021 Apr 7;12:645170. doi: 10.3389/fimmu.2021.645170. eCollection 2021.
10
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.头颈部鳞状细胞癌微环境中的程序性死亡受体配体1（PD-L1）表达及对检查点抑制剂的反应
Oncoimmunology. 2020 Nov 19;9(1):1844403. doi: 10.1080/2162402X.2020.1844403.
引用本文的文献
1
[Significance of neoadjuvant immunotherapy combined with chemotherapy in the treatment of larynx preservation in locally advanced hypopharyngeal squamous cell carcinoma].新辅助免疫治疗联合化疗在局部晚期下咽鳞状细胞癌喉保留治疗中的意义
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Sep;37(9):715-720;728. doi: 10.13201/j.issn.2096-7993.2023.09.006.
2
[Tislelizumab monotherapy for the treatment of recurrent/metastatic head and neck squamous cell carcinoma].替雷利珠单抗单药治疗复发性/转移性头颈部鳞状细胞癌
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Oct;37(10):778-785. doi: 10.13201/j.issn.2096-7993.2023.10.003.
本文引用的文献
1
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.肿瘤浸润淋巴细胞治疗抗 PD-1 耐药性转移性肺癌：一项 1 期试验。
Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12.
2
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.NRG-HN003：帕博利珠单抗、顺铂和放射治疗用于病理高危头颈癌辅助治疗的I期及扩展队列研究。
Cancers (Basel). 2021 Jun 9;13(12):2882. doi: 10.3390/cancers13122882.
3
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.头颈部局部晚期可切除皮肤鳞状细胞癌新辅助免疫治疗的 II 期临床试验。
Clin Cancer Res. 2021 Aug 15;27(16):4557-4565. doi: 10.1158/1078-0432.CCR-21-0585. Epub 2021 Jun 29.
4
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.西妥昔单抗与纳武单抗联合用于复发和/或转移性头颈部鳞状细胞癌患者的二线及以上治疗：I/II期研究结果
Cancers (Basel). 2021 Mar 9;13(5):1180. doi: 10.3390/cancers13051180.
5
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma.KEYNOTE-022 研究第 3 部分：帕博利珠单抗、达拉非尼和曲美替尼治疗 - 突变黑色素瘤的随机、双盲、2 期研究。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001806.
6
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.联合治疗在PD1/PDL1抑制剂临床试验中占据核心地位。
Nat Rev Drug Discov. 2021 Mar;20(3):168-169. doi: 10.1038/d41573-020-00204-y.
7
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).avelumab-西妥昔单抗-放疗与头颈部局部晚期鳞状细胞癌的标准治疗比较：GORTEC 2017-01（REACH）随机 III 期试验的安全性阶段。
Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24.
8
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.顺铂/多西他赛/度伐利尤单抗/曲美木单抗单周期诱导治疗局部晚期头颈部鳞状细胞癌的安全性和疗效：CheckRad-CD8的初步结果
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001378.
9
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.随机Ⅱ期试验：纳武利尤单抗联合立体定向体部放疗对比纳武利尤单抗单药治疗转移性头颈部鳞状细胞癌。
J Clin Oncol. 2021 Jan 1;39(1):30-37. doi: 10.1200/JCO.20.00290. Epub 2020 Aug 21.
10
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.可切除局部晚期、人乳头瘤病毒无关的头颈部癌新辅助和辅助帕博利珠单抗治疗：一项多中心、Ⅱ期试验。
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14.
Zotero 插件